ADVERTISEMENT
Modified FOLFOXIRI Plus Cetuximab as the First-Line Treatment for Patients With RAS Wild-Type Metastatic Colorectal Cancer
Updated Survival Data From the Phase 2 DEEPER Trial
Updated Survival Data From the Phase 2 DEEPER Trial
At the 2023 ESMO World Congress on Gastrointestinal Cancers, Yu Sunakawa, MD, St. Marianna University School of Medicine, Kawasaki, Japan, presented updated survival data from the phase 2 DEEPER trial, evaluating modified(m)-FOLFOXIRI plus cetuximab vs m-FOLFOXIRI plus bevacizumab among patients with RAS wild-type metastatic colorectal cancer. Previously, it was reported that mFOLFOXIRI plus cetuximab showed significant better depth of response.
From this updated data, Dr Sunakawa concluded, “The modified-FOLFOXIRI plus cetuximab regimen could be a good option for upfront chemotherapy in metastatic colorectal cancer patients with RAS/BRAF wild-type and left-sided primary tumors.”
Transcript:
Source:
Sunakawa Y, Shiozawa M, Watanabe, T, et al. Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment for RAS and BRAF wild-type metastatic colorectal cancer: Updated survival analysis of the DEEPER trial by JACCRO. Presented at the 2023 ESMO World Congress on Gastrointestinal Cancers; June 28-July 1, 2023; Barcelona, Spain. Abstract SO-25